News | August 11, 2021
Cadila Healthcare net profit at Rs 587.2 cr in Q1FY22
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
A total of 526 brands has seen a reduction of up to 90 per cent in MRP
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
Nearly 6,000 patients have been treated with the drug since 2017
Deal signed with AOP Orphan for US commercial rights
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
The drug is indicated for mild and transient episodes of heart block
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Subscribe To Our Newsletter & Stay Updated
